Rhenman & Partners Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Rhenman & Partners Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-650,000	Closed	-$3.15M	–	99
2020 Q1	$3.15M	Sell	650,000 -110,181	-14%	-$714K	0.44%	64
2019 Q4	$8.08M	Buy	760,181 +249,158	+49%	+$2.47M	0.89%	48
2019 Q3	$5.32M	Buy	511,023 +17,024	+3%	+$223K	0.67%	55
2019 Q2	$7.57M	Buy	+493,999	New	+$7.15M	0.83%	49

Rhenman & Partners Asset Management's STML Position: Q2 2020 in Review

Rhenman & Partners Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 650,000 shares — an estimated $3.15M sold.

Rhenman & Partners Asset Management first reported a position in STML in Q2 2019 and held it in 4 quarters. The position peaked at $8.08M in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Rhenman & Partners Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Rhenman & Partners Asset Management sold 650,000 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $3.15M.
Rhenman & Partners Asset Management first reported a position in Stemline Therapeutics, Inc. in Q2 2019 and held it in 4 quarters.
Rhenman & Partners Asset Management's Stemline Therapeutics, Inc. position peaked at $8.08M in Q4 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2020, filed 16 Jul 2020.